Focus: Phoenix PharmaLabs is a 5,000+ employee private biotechnology company headquartered in Utah specializing in opiate addiction treatments, though currently generating 100% revenue from a generic corticosteroid portfolio.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Phoenix PharmaLabs to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue generator generating only $8M Part D spend; post-LOE status indicates eroding exclusivity and limited growth upside.
Help build intelligence for Phoenix PharmaLabs
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Phoenix PharmaLabs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Pre-launch generic antihistamine; minimal revenue potential and low therapeutic differentiation.
Pre-launch generic corticosteroid with highly competitive market; unlikely to meaningfully offset dexamethasone decline.
Pre-launch generic corticosteroid competing in crowded therapeutic space with limited differentiation.
Post-LOE generic tuberculosis drug with off-label leukemia indication; marginal commercial relevance.
5 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub